FDA’s Social Media Guidance: As Industry Waits, How Watchful Should It Be?
This article was originally published in The Pink Sheet Daily
Executive Summary
In the absence of clear policy from the agency, GSK keeps careful eyes on Facebook, but experts disagree on the extent to which drug companies are required to actively monitor social media sites.
You may also be interested in...
The Consequences of Caronia: Impact On FDA’s Off-Label Regulation
The government has decided not to appeal the Second Circuit’s Caronia off-label promotion ruling – no doubt in part because of concerns about the broad reading of the First Amendment currently in favor at the Supreme Court. Officially, FDA has adopted a low-key response. Unofficially, agency officials – notably Bob Temple – are outraged by the ruling. What does Caronia mean for the future of FDA regulation and off-label prosecutions?
FDA Revises Prescriber DTC Survey To Focus On Patient Interactions
The agency appeared unusually receptive to outside suggestions about a proposed questionnaire, dropping questions related to drug pricing and adding ones about exam room conversations.
FDA Gets Social, But Not Too Social
FDA is trying multiple channels in social media to communicate drug safety information, but its two-way communication capacity is lower than many would like.